Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

The percentage of national populations infected during the first stages of the COVID-19 pandemic are unclear owing to limited early testing. Here the authors provide a nation-wide prevalence study of SARS-CoV-2 antibodies in France from the first wave of COVID-19 in 2020, including stratification ba...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stéphane Le Vu, Gabrielle Jones, François Anna, Thierry Rose, Jean-Baptiste Richard, Sibylle Bernard-Stoecklin, Sophie Goyard, Caroline Demeret, Olivier Helynck, Nicolas Escriou, Marion Gransagne, Stéphane Petres, Corinne Robin, Virgile Monnet, Louise Perrin de Facci, Marie-Noelle Ungeheuer, Lucie Léon, Yvonnick Guillois, Laurent Filleul, Pierre Charneau, Daniel Lévy-Bruhl, Sylvie van der Werf, Harold Noel
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/53e4ab675fd743dc9696f2feeb701868
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53e4ab675fd743dc9696f2feeb701868
record_format	dspace
spelling	oai:doaj.org-article:53e4ab675fd743dc9696f2feeb7018682021-12-02T14:58:51ZPrevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance10.1038/s41467-021-23233-62041-1723https://doaj.org/article/53e4ab675fd743dc9696f2feeb7018682021-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23233-6https://doaj.org/toc/2041-1723The percentage of national populations infected during the first stages of the COVID-19 pandemic are unclear owing to limited early testing. Here the authors provide a nation-wide prevalence study of SARS-CoV-2 antibodies in France from the first wave of COVID-19 in 2020, including stratification based on age, sex and region.Stéphane Le VuGabrielle JonesFrançois AnnaThierry RoseJean-Baptiste RichardSibylle Bernard-StoecklinSophie GoyardCaroline DemeretOlivier HelynckNicolas EscriouMarion GransagneStéphane PetresCorinne RobinVirgile MonnetLouise Perrin de FacciMarie-Noelle UngeheuerLucie LéonYvonnick GuilloisLaurent FilleulPierre CharneauDaniel Lévy-BruhlSylvie van der WerfHarold NoelNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Stéphane Le Vu Gabrielle Jones François Anna Thierry Rose Jean-Baptiste Richard Sibylle Bernard-Stoecklin Sophie Goyard Caroline Demeret Olivier Helynck Nicolas Escriou Marion Gransagne Stéphane Petres Corinne Robin Virgile Monnet Louise Perrin de Facci Marie-Noelle Ungeheuer Lucie Léon Yvonnick Guillois Laurent Filleul Pierre Charneau Daniel Lévy-Bruhl Sylvie van der Werf Harold Noel Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
description	The percentage of national populations infected during the first stages of the COVID-19 pandemic are unclear owing to limited early testing. Here the authors provide a nation-wide prevalence study of SARS-CoV-2 antibodies in France from the first wave of COVID-19 in 2020, including stratification based on age, sex and region.
format	article
author	Stéphane Le Vu Gabrielle Jones François Anna Thierry Rose Jean-Baptiste Richard Sibylle Bernard-Stoecklin Sophie Goyard Caroline Demeret Olivier Helynck Nicolas Escriou Marion Gransagne Stéphane Petres Corinne Robin Virgile Monnet Louise Perrin de Facci Marie-Noelle Ungeheuer Lucie Léon Yvonnick Guillois Laurent Filleul Pierre Charneau Daniel Lévy-Bruhl Sylvie van der Werf Harold Noel
author_facet	Stéphane Le Vu Gabrielle Jones François Anna Thierry Rose Jean-Baptiste Richard Sibylle Bernard-Stoecklin Sophie Goyard Caroline Demeret Olivier Helynck Nicolas Escriou Marion Gransagne Stéphane Petres Corinne Robin Virgile Monnet Louise Perrin de Facci Marie-Noelle Ungeheuer Lucie Léon Yvonnick Guillois Laurent Filleul Pierre Charneau Daniel Lévy-Bruhl Sylvie van der Werf Harold Noel
author_sort	Stéphane Le Vu
title	Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
title_short	Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
title_full	Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
title_fullStr	Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
title_full_unstemmed	Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
title_sort	prevalence of sars-cov-2 antibodies in france: results from nationwide serological surveillance
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/53e4ab675fd743dc9696f2feeb701868
work_keys_str_mv	AT stephanelevu prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT gabriellejones prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT francoisanna prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT thierryrose prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT jeanbaptisterichard prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT sibyllebernardstoecklin prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT sophiegoyard prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT carolinedemeret prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT olivierhelynck prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT nicolasescriou prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT mariongransagne prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT stephanepetres prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT corinnerobin prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT virgilemonnet prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT louiseperrindefacci prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT marienoelleungeheuer prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT lucieleon prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT yvonnickguillois prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT laurentfilleul prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT pierrecharneau prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT daniellevybruhl prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT sylvievanderwerf prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance AT haroldnoel prevalenceofsarscov2antibodiesinfranceresultsfromnationwideserologicalsurveillance
_version_	1718389264697262080

Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

Ejemplares similares